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Until recently, the brain was studied almost exclusively by neuroscientists and the immune system by immu-
nologists, fuelling the notion that these systems represented two isolated entities. However, as more data
suggest an important role of the immune system in regulating the progression of brain aging and neurode-
generative disease, it has become clear that the crosstalk between these systems can no longer be ignored
and a new interdisciplinary approach is necessary. A central question that emerges is whether immune and
inflammatory pathways become hyperactivated with age and promote degeneration or whether insufficient
immune responses, which fail to cope with age-related stress, may contribute to disease. We try to explore
here the consequences of gain versus loss of function with an emphasis on microglia as sensors and effec-
tors of immune function in the brain, and we discuss the potential role of the peripheral environment in neuro-
degenerative diseases.Introduction
More than a half century ago, Peter Medawar noted a curious
phenomenon. When heterologous tissues were transplanted
into the CNS, he noticed that they were spared from immunolog-
ical rejection (Medawar, 1948). This finding led him to speculate
that the brain and immune system existed as two isolated
systems. Until recently, this dogma was generally accepted,
and brain immune responses were only studied in a few
‘‘immune-mediated’’ diseases. However, epidemiological stud-
ies revealing that long-term use of anti-inflammatory drugs
reduces the risk for Alzheimer’s (AD) and Parkinson’s disease
(PD) by roughly half hinted at a role for inflammation in classical
age-related neurodegeneration (Chen et al., 2005; McGeer et al.,
1996; Vlad et al., 2008). Growing evidence now suggests that the
brain and immune system are intricately connected and engage
in significant crosstalk tomaintain homeostasis. Indeed, immune
cells and mediators are routinely found in the CNS under normal
and pathological states, while neurons are capable of interacting
with and regulating immune cells. Neurodegenerative diseases
also exhibit extensive microglial activation (the immune cells of
the brain). Elegant studies combining mouse models that have
various immune defects (developed by immunologists) with
transgenic models for neurodegenerative diseases further impli-
cate the immune system in disease progression by showing that
lymphocytes play a role in PD, amyotrophic lateral sclerosis
(ALS), and possibly AD. Interestingly, normal aging also exhibits
immune activation and cell infiltration in the brain. Despite these
commonalities, the role of the immune system in aging and
neurodegenerative disease remains unclear. Here, we discuss
some of the new and exciting findings that provide insight into
how the immune system affects neurodegenerative disease
and aging. Specifically, we will discuss how the immune system
is activated and regulated in an aged and injured brain and
whether impaired immune functionmay lead to the accumulation
of protein aggregates in neurodegenerative disease.110 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.Microglia: A Sensor of Brain Injury and Aging
A basic feature of all living organisms is the ability to detect
potentially harmful stimuli and react accordingly. In the brain,
glial cells constantly survey the microenvironment for noxious
agents or injurious processes (Nimmerjahn et al., 2005). This is
primarily done by microglia, a type of glial cell derived from
myeloid precursors in the bone marrow that populate the CNS
during development. Microglia are the resident immune cells of
the brain and are endowed with numerous receptors capable
of detecting physiological disturbances (see Figure 1). When
neurons are injured as a result of aging or neurodegeneration,
microglia become activated via the release of ATP, neurotrans-
mitters, growth factors or cytokines, ion changes in the local
environment, or loss of inhibitor molecules displayed by healthy
neurons (Hanisch and Kettenmann, 2007). Microglia are also
alerted that something is wrong when they encounter molecules
not normally found in the healthy CNS, such as blood clotting
factors, intracellular constituents released by necrotic cells
(i.e., RNA, DNA), externalized phosphatidylserine on apoptotic
cells, immunoglobulin-antigen complexes, opsonizing comple-
ment, abnormally folded proteins (i.e., protein aggregates), or
pathogen-related structures (Hanisch and Kettenmann, 2007).
Upon activation, microglia may proliferate and undergo a
morphological transformation from a ramified to amoeboid
appearance. Based on the activation stimuli, microglia are
informed of the encountered problem and instructed to act in
an appropriate manner and perform a defined task (e.g., clear
apoptotic cells or abnormal proteins). If the disturbance is rela-
tively minor (e.g., supporting a stressed neuron), microglia may
secrete anti-inflammatory cytokines and supportive growth
factors. If the disturbance poses a serious threat, such as a path-
ogen invasion, microglia may release toxic factors to kill the
pathogen and recruit help by releasing proinflammatory cyto-
kines (Figure 1). Depending on the environment in which micro-
glia are activated, they can either take on a ‘‘classically
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ReviewFigure 1. Regulation of Microglia/Macrophages in the CNS
Microglia/macrophages are activated following the stimulation of various recognition or phagocytic receptors. This activation state is subsequently controlled by
neurons, which secrete or express numerous regulatory ligands. The end result of these interactions is the release of cytokines, neurotoxic substrates, and/or
growth factors by microglia/macrophages or the activation of cellular pathways including phagocytosis. Aberrant function of these pathways can result in signif-
icant degeneration during aging or disease. For an extensive review of cytokines and chemokines recognized bymicroglia, refer to Hanisch (2002). Ab, amyloid-b;
ADP/ATP, adenosine di/triphosphate; AGE, advanced glycation end product; BDNF, brain-derived neurotrophic factor; EGF, epidermal growth factor; GABA,
gamma-aminobutyric acid; H2O2, hydrogen peroxide; HMGB1, high-mobility group box 1; IL-1b, interleukin 1b; LPS, lipopolysaccharide; MCP-1, monocyte
chemotactic protein-1; MCSF, macrophage colony-stimulating factor; NGF, nerve growth factor; NO, nitric oxide; NOO, peroxynitrite; NT-3,4, neurotrophin-
3,4; O2
, superoxide; PACAP, pituitary adenylate cyclase-activating peptide; PS, phosphatidylserine; RAGE, receptor for advanced glycation end products;
RANTES, regulated upon activation, normal T cell expressed and secreted; TGF-b, transforming growth factor-b; TLR, toll-like receptor; TNFa, tumor necrosis
factor-a; TREM2, triggering receptor expressed by myeloid cells-2; UDP/UTP, uridine di/triphosphate. Receptors displayed inside the cell represent intracellular
receptors. Different receptor shapes are not meant to represent actual receptor structures.activated’’ (also called M1) phenotype or an ‘‘alternatively
activated’’ (also called M2) phenotype (Mantovani et al., 2004).
M2 microglia are typically considered less inflammatory than
M1 cells and are characterized by reduced nitric oxide produc-
tion and increased anti-inflammatory cytokine production.
Accordingly, microglial heterogeneity exists during neurodegen-
erative disease and may influence disease outcome (Colton
et al., 2006; Maier et al., 2008). Given the continuum of potential
microglial responses, how a given insult is interpreted can
mean the difference between a beneficial outcome or a detri-
mental outcome if the response is either too aggressive or too
passive.PAMPs and DAMPs Sound the Alarm
In order to detect and interpret potential insults, the immune
system has evolved an ingenious set of receptors that detect
small molecular motifs consistently found on pathogens or
factors associated with tissue damage. Detection of these exog-
enous pathogen-associated molecular patterns (PAMPs) or
endogenous danger-associated molecular patterns (DAMPs)
is accomplished by a vast array of highly conserved pattern-
recognition receptors (Janeway and Medzhitov, 2002; Seong
and Matzinger, 2004). While toll-like receptors (TLRs) have
received the most attention for their ability to recognize both
classes of these molecular patterns (see below), many otherNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 111
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described (e.g., complement, mannose, scavenger, C-type
lectin, nucleotide-binding oligomerization domain [Nod]-like
[including NALP3 and NOD2], and retinoic acid-inducible gene I
[RIG-I]-like helicase receptors) (Palm and Medzhitov, 2009).
Additional receptors also exist that appear to selectively recog-
nize DAMPs, including CD24 and receptor for advanced glyca-
tion end-products (RAGE) (Arancio et al., 2004; Chen et al., 2009).
To date, 13 TLRs have been described that collectively recog-
nize various PAMPs essential for pathogen survival (reviewed by
Iwasaki and Medzhitov, 2004). TLRs are expressed on a variety
of immune cells, including macrophages, dendritic cells, B cells,
specific types of T cells, and even nonimmune cells such as
epithelial cells, fibroblasts, and neurons. Stimulation of TLRs
induces a well-characterized signaling cascade, culminating in
the activation of nuclear factor kB and subsequent transcrip-
tional activation of numerous proinflammatory genes, encoding
cytokines, chemokines, complement proteins, enzymes (such
as cyclooxygenase 2 and the inducible form of nitric oxide syn-
thase), adhesion molecules, and immune receptors (Nguyen
et al., 2002). In the face of an invading pathogen, these factors
allow for a robust and coordinated immune response capable
of eradicating infectious pathogens. While this approach is
highly effective for eliminating pathogens, it comes at the
expense of extensive bystander injury. Indeed, CNS microinjec-
tions of the TLR 2 or 4 ligands zymosan and LPS, respectively,
cause robust glial activation and elicit substantial neurodegener-
ation (Lehnardt et al., 2003; Popovich et al., 2002). This becomes
increasingly problematic when one considers that TLRs can also
be engaged by DAMP-containing molecules released by CNS
trauma or disease (e.g., heat-shock proteins [HSPs], high-
mobility-group box protein 1 [HMGB1], fibrinogen, hypomethy-
lated mammalian DNA, and RNA released from necrotic cells)
(Kariko et al., 2004; Leadbetter et al., 2002; Ohashi et al.,
2000; Smiley et al., 2001; Viglianti et al., 2003). In support of
this, TLR4-deficient mice have smaller infarct volumes and
better functional outcomes than control mice in a sterile model
of experimental stroke (Caso et al., 2007). One explanation for
this finding is that HSP60, a molecule released from CNS cells
undergoing necrotic or apoptotic cell death, activates microglia
via TLR4 and causes enhanced nitric oxide production and
neuronal cell death (Lehnardt et al., 2008). Interestingly, TLR2
and -4 are upregulated on cerebral cortical neurons in response
to ischemia/reperfusion injury, and their absence protects
primary neuron cultures from energy-deprivation-induced cell
death (Tang et al., 2007). Given these observations, it is tempting
to speculate that the concerted increase in expression of
multiple TLRs in the aging brain (Berchtold et al., 2008; Letiem-
bre et al., 2007) may generate a hypersensitive state of glia and
neurons and thus magnify potential bystander injury. Exactly
how neuronal TLRs promote neurodegeneration and the identity
of their ligands is currently unclear. Additional studies are
required to elucidate these mechanisms using more precise
neuron-specific TLR-deficient mice.
While ischemia and subsequent necrosis may initiate neuroin-
flammation and provoke further neurodegeneration in models of
acute neurological disease and trauma, they are unlikely to play
a role in chronic neurodegenerative disorders where necrotic112 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.conditions are uncommon. Instead, abnormal protein assem-
blies can function as a possible trigger for cellular stress and
neuroinflammation. Most neurodegenerative disorders are asso-
ciated with the accumulation of abnormal protein assemblies
(proteopathies) (Orr and Zoghbi, 2000; Sherman and Goldberg,
2001; Walker and LeVine, 2000), some of which result from
specific genetic mutations. A common feature of these abnormal
protein aggregates, which may occur inside cells or in the extra-
cellular space, is the existence of b sheets, as detected by stain-
ing with Congo red or related dyes and referred to as amyloid.
Interestingly, bacteria produce similar amyloidogenic aggre-
gates on their cell surface that bind Congo red (Chapman
et al., 2002; Hammer et al., 2007). This begs the question of
whether amyloid structures act as PAMPs and are interpreted
as invading pathogens that elicit an aggressive neurotoxic
response. In line with this hypothesis, Ab is known to bind the
TLR4 coreceptor CD14 (Fassbender et al., 2004; Liu et al.,
2005) and can trigger microglia to secrete nitric oxide, interleukin
(IL)-6, and other neurotoxic factors (Walter et al., 2007). Consis-
tent with this, levels of tumor necrosis factor (TNF)-a and macro-
phage inflammatory protein (MIP)-1b are significantly higher in
the brains of AD mice with wild-type TLR4 than their mutant
TLR4 AD counterparts (Jin et al., 2008). On the other hand,
TLR-mediated activation of microglia may also aid in the clear-
ance of Ab. Studies in AD mouse models with mutant TLR2 or
TLR4 suggest that deficiencies in TLR signaling causes cognitive
impairments with a concomitant increase in Ab deposition
(Richard et al., 2008; Tahara et al., 2006). Likewise, acute admin-
istration of the TLR4 ligand LPS can promote Ab clearance
(DiCarlo et al., 2001), and studies in mouse models of ALS
suggest that TLR signaling is protective in disease progression
(Kang and Rivest, 2007). Whether these receptors normally
exacerbate neurodegeneration or guide the clearance of protein
aggregates is still largely unknown andmany studies, particularly
with Ab, do not consider the aggregation state of the peptide. It is
thus likely that different receptors will be engaged bymonomers,
oligomers, or fibrillar assemblies of Ab and that other amyloido-
genic peptides may elicit different types of responses in micro-
glia (and other cells).
The Complex Life of Complement
Complement proteins represent another line of defense in recog-
nizing PAMPs and DAMPs and act as secreted pattern-recogni-
tion receptors. Using a collagen-like receptor binding domain
and multiple globular domains, complement component C1
bindsmolecular patterns onmicrobes, dying cells, and abnormal
protein aggregates (Tenner, 1999). Although the liver is the major
source of complement, neurons and glia can make nearly all of
the 30 different proteins involved in the complement cascade.
During AD (Akiyama et al., 2000; Gasque et al., 2000), HD (Singh-
rao, 1999), PD (Yamada et al., 1992), and prion disease (Dandoy-
Dron et al., 1998), levels of various complement components
increase. An increase in complement proteins C1q, mannose
binding lectin, and C3 can all initiate neuroinflammatory
processes by activating inflammatory cells, promoting their
migration, upregulating phagocytosis, and facilitating lysis by
the membrane attack complex (Holers, 1996; Song et al.,
2000). In AD, complement products, including the membrane
Neuron
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bearing neurons (Webster et al., 1997). APP mouse models
where C3 activation is inhibited, via overexpressing soluble
complement receptor-related protein y (sCrry), find an increase
in Ab deposition and an accumulation of degenerating neurons
(Wyss-Coray et al., 2002). In support of this, APP mice with
a complete knockout of C3 also show increased Ab and neuronal
degeneration, accompanied by changes in microglial activation
(Maier et al., 2008). These data suggest that C3 may work with
microglia to effectively clear Ab. Alternatively, C3 may act in
the periphery to clear circulating Ab by creating a peripheral
sink, as previously proposed (DeMattos et al., 2001). Indeed,
studies show that Ab binds to complement receptor 1 on red
blood cells in a C3-dependent manner and that AD patients in
their earliest stages have significantly less Ab bound to red blood
cells (Rogers et al., 2006). Because the genetic manipulations
were systemic in the previously mentioned studies (Wyss-Coray
et al., 2002; Maier et al., 2008), this theory cannot be ruled out.
Studies using sCrry under the GFAP or hepatocyte-specific
transthyretin promoters could shed light on this question.
But again, complement proteins like other immune factors can
have detrimental effects. APP mice lacking complement C1q
had less neuronal damage than complement-sufficient mice,
suggesting a role for C1q in neuronal integrity (Fonseca et al.,
2004). Indeed, C1q and C3 have recently been shown tomediate
synaptic pruning during development and in a model of glau-
coma, opening the possibility that complement factors may
contribute to aberrant elimination of synapses in neurodegener-
ative diseases (Stevens et al., 2007).
Microglia in Neurodegeneration: Repairman
or Reckless Killer?
Maybe 90%of published articles onmicroglia in neurodegenera-
tion link activation of these cells with proinflammatory cytokine
production and execution of neuronal cell death. Thus, microglia
are thought to be responsible for killing dopaminergic cells in PD
(Mount et al., 2007) and forebrain neurons in AD, and they have
been shown to contribute to neurodegeneration in SOD1 trans-
genic mouse models for ALS (Boillee et al., 2006). Microglial-
derived factors capable of inducing neuron death are numerous
and range from reactive oxygen species toproinflammatory cyto-
kines (see Figure 1). TNF-a is one such factor that has received
much attention because of its ability to promote PD progression
(McCoy et al., 2006), while TNF receptor 1 knockout protects
against AD- and PD-like disease in mice (He et al., 2007; Sriram
et al., 2002). Inhibiting the neurotoxic potential of proinflamma-
tory cytokines is also likely to contribute to the beneficial effects
ofNSAIDsonneurodegenerative diseases. Interestingly, ablating
reactive microglia by 50% in a model of ALS has no effect on
motor neuron degeneration, suggesting that deleterious micro-
glial function may be context dependent (Gowing et al., 2008).
Clearly in most cases hyperactivated microglia can be delete-
rious and must be regulated to prevent neuronal damage.
Keeping the Beast in Check: Neurons
as Tamers of Microglia
Interestingly, the brain has evolved various safety measures to
keep microglia in check (Figure 1). These mechanisms allowneurons to downregulate microglial function until neuronal health
is compromised. For example, CD200 is a membrane glycopro-
tein expressed by neurons that interacts with its cognate
receptor on microglia (CD200R) to deliver regulatory signals.
When mice are genetically deficient in CD200, microglial reac-
tivity is enhanced under normal and pathological conditions
(i.e., EAE and facial nerve axotomy) (Hoek et al., 2000). Similar
to CD200, the integrin-associated protein CD47 is expressed
by neurons and when bound to its receptor on microglia (SIRPa;
CD172a) inhibits TNF-a release and phagocytosis (Oldenborg
et al., 2001; Smith et al., 2003). These regulatory molecules
appear to be relevant to humans as well, given that both CD47
and CD200 are downregulated in the center of chronic active
and inactive human MS lesions, suggesting a possible role in
propagating microglial activation and proinflammatory cytokine
release (Koning et al., 2007). Fractalkine (CX3CL1) is another
ligand expressed by neurons that restricts microglial activation
when bound to its receptor (CX3CR1) (Cardona et al., 2006).
This ligand-receptor interaction is absent when neurons die or
are damaged, resulting in hyperresponsive microglia. Accord-
ingly, in mouse models of Parkinson’s disease or ALS, lack of
CX3CR1 leads to extensive neuronal cell loss (Cardona et al.,
2006). Microglia also express CD14, CD36, and phosphatidyl-
serine receptors that, when bound to specific ligands on
apoptotic cells (i.e., neurons), trigger inhibitory intracellular
signals that reduce nitric oxide and proinflammatory cytokine
release, while concomitantly increasing anti-inflammatory cyto-
kine production (Savill et al., 2002). Triggering receptor ex-
pressed by myeloid cells-2 (TREM2) is an additional receptor
on microglia that promotes phagocytosis and retards inflamma-
tion upon binding unknown ligands on apoptotic cells (Hsieh
et al., 2009). When neurons are stressed, they can secrete sem-
aphorin 3A and induce apoptosis of activated microglia, which
express upregulated levels of the semaphorin receptors plexin-
A1 and neuropilin-1 (Majed et al., 2006). This response is thought
to protect neurons from further microglia-mediated damage.
Neurons also release the anti-inflammatory neuropeptide CD22
from their nerve terminals, which regulates microglia activation
and proinflammatory cytokine production via its receptor CD45
(Mott et al., 2004). Various secreted neurotransmitters have
also shown similar modulatory effects on microglia (Pocock
and Kettenmann, 2007), and suppressing spontaneous neuronal
activity increases immune reactivity (Neumann et al., 1996). It
should be noted that these regulatory mechanisms may prevent
damage, but the extent to which they inhibit inherent repair
mechanisms is unclear. More sophisticated tetracycline-induc-
ible promoters or pharmacological tools are required to address
whether intervening with these processes at defined time points
may provide significant therapeutic benefit.
Do Changes in Brain and Microglial Function
with Age Promote Neurodegeneration?
Althoughmicroglia are typically regarded as robust proinflamma-
tory minutemen, microglia existing within an aging environment
may be a different beast altogether. Aging is the strongest risk
factor for neurodegenerative diseases, and while aging is not
considered a disease, it results in a significant increase in glial
activation (see Figure 2), complement factors, inflammatoryNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 113
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ReviewFigure 2. Increased Microglial Activation in
the Aged Brain
Immunostaining for the endosomal/lysosomal
enzyme CD68, a marker of the microglia/macro-
phage lineage, shows a prominent increase in
the neocortex of 24-month-old C57BL/6 mouse
(B) compared with a 6-month-old mouse (A),
consistent with increased microglial activation in
aged brains. Inserts show individual microglia
under higher magnification where hypertrophied
cell bodies are evident in aged brains (compare
insert A to B). Scale bars represent 50 mm under
203 or 403 magnification.mediators, and brain atrophy (Lu et al., 2004; Streit et al., 2008;
West et al., 1994). Microarrays of aged human and mouse brains
extend these findings by showing that genes related to cellular
stress and inflammation increase with age while genes related
to synaptic function/transport, growth factors, and trophic
support decrease (Lee et al., 2000; Lu et al., 2004). These global
changes paint a bleak picture of the aged brain and suggest
that neuronsencounter increasedchallengeswith agebut receive
reduced support. To make matters worse, neurogenesis also
decreases with age—possibly as a result of factors secreted by
activated microglia (i.e., IL-6) (reviewed in detail in Carpentier
and Palmer [2009], this issue of Neuron; also see Monje et al.,
2003). It is unclear why inflammation increases with age, but
genetic studies suggest an important role ofDNAdamagecaused
by increased reactive oxygen species (Lu et al., 2004). Also
unclear is to what extent aging affects the responsiveness of mi-
croglia or their potential to contribute to neuronal loss. Despite
morphological and phenotypic changes that indicate microglial
activation (Figure 2), it has been proposed that microglia may
actually become dysfunctional and enter a senescent state with
age (Streit et al., 2008). Such a state may cause microglia to
secrete diminished levels of neurotrophic factors and to downre-
gulate phagocytic function. This, coupled with increased secre-
tion of inflammatory mediators, may lead to neuronal loss and
inefficient clearance of toxic protein aggregates in neurodegener-
ative disease.
Impaired Trash Removal as a Risk Factor
for Neurodegeneration?
The accumulation of protein aggregates in neurodegenerative
diseases may occur from enhanced production of abnormal
proteins or abnormal folding. Alternatively, accumulating protein
aggregates may result from insufficient clearance. Recent
evidence suggests that impaired autophagy is one mechanism
that influences the clearance of protein aggregates and neurode-
generative disease pathogenesis (Pickford et al., 2008; Raviku-
mar et al., 2004). Autophagy (also known as macroautophagy)
is the major pathway involved in the degradation of long-lived
proteins (Klionsky and Emr, 2000). Autophagy is highly
conserved in all species and cell types studied thus far. It is initi-
ated by the formation of a cup-shaped isolation membrane
around cytosolic components, which eventually encloses to
form a double membrane vesicle (two bilayered membranes)114 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.(Wang and Klionsky, 2003). This autophagosome undergoes
several microtubule-dependent maturation events before even-
tually fusing with lysosomes, where cytosolic contents are
degraded (Berg et al., 1998). Autophagy is impaired in AD (Nixon
et al., 2005) and is implicated in the clearance of protein aggre-
gates associated with AD, PD, and HD (Pickford et al., 2008;
Ravikumar et al., 2004;Webb et al., 2003). The exact mechanism
by which protein aggregates are targeted during autophagy is
unclear. One possible link for intracellular aggregates is the
protein sequestosome 1 (SQSTM1, also known as p62), which
binds both ubiquitin (protein aggregates are often polyubiquiti-
nated) and the autophagosome protein MAP1LC3 (Pankiv
et al., 2007). Also unclear is which cell type(s) are influenced by
autophagy to regulate levels of protein aggregates. Given that
many protein aggregates have an intraneuronal component
that may precede extracellular deposition, neurons are likely
a target of critical importance (for further review see Jaeger
and Wyss-Coray, 2009). However, emerging evidence also indi-
cates a link between autophagy and phagocytic function in
microglia/macrophages (see below).
Extracellular clearance of debris is classically attributed to
phagocytes such as the peripheral macrophage, which literally
means ‘‘big eater’’ (derived from the Greek words makros
‘‘large’’ + phagein ‘‘eat’’). These bone-marrow-derived cells
accomplish clearance of debris via phagocytosis, a receptor-
mediated process whereby engagement of specific receptors
(e.g., PAMPs and DAMPs) triggers actin polymerization and
engulfment into specialized vesicles called phagosomes. The
phagosome is internalized and fuses with lysosomes where its
contents are degraded. Evidence for autophagy interacting
with phagocytosis was first discovered in studies utilizingMyco-
bacterium tuberculosis, which is a bacterium that persists in
macrophage phagosomes by interfering with phagolysosome
biogenesis (Gutierrez et al., 2004). Promoting autophagy in
infected macrophages caused colocalization of the autophagy
effectors LC3 with phagosomes and suppressed intracellular
survival of mycobacteria (Gutierrez et al., 2004). Using more
elegant methods to establish a connection between autophagy
and phagocytosis in macrophages, proteomic analysis on the
membrane fraction of latex-bead-containing phagosomes
revealed the presence of LC3-II (Shui et al., 2008). Recent
studies have strengthened this connection and additionally sug-
gested that TLR-2 and -4 stimulation during macrophage
Neuron
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assists in phagosome maturation (Sanjuan et al., 2007). It is
now clear that various TLR ligands activate autophagy in macro-
phages (Delgado et al., 2008; Xu et al., 2007). Because TLRs can
recognize pathogenic protein aggregates, collaboration
between autophagy and phagocytosis may represent a newly
recognized innate defense mechanism for eliminating abnormal
protein aggregates. Therefore, deficits in autophagy, as seen in
AD (Pickford et al., 2008), may actually have mutually exclusive
effects on the clearance of intraneuronal aggregates by macro-
autophagy and extracellular aggregates by phagocytosis.
While this newly emerging collaboration between autophagy
and phagocytosis is intriguing in the context of neurodegenera-
tion, triggering classical phagocytosis in the CNS may also
directly improve clearance of aggregates. During acute CNS
injury, when the blood-brain barrier (BBB) is severely compro-
mised and robust inflammation is elicited, blood-derived macro-
phages (known as monocytes) infiltrate the CNS and contribute
to the pathological sequelae. Unfortunately, CNS-resident
microglia and blood-derived monocytes entering the CNS take
on similar morphological and phenotypic profiles, currently
making the two cell populations almost indistinguishable.
Chronic neurodegenerative disease (e.g., AD and PD) causes
only subtle inflammation, and the contribution of blood-derived
monocytes is controversial (see below). However, what is clear
is that microglia and astrocytes are activated and produce an
array of inflammatory mediators, while upregulating phagocytic
activity (Aldskogius et al., 1999). Using in vivo multiphoton
imaging, the specific kinetics of this response were recently
revealed (Meyer-Luehmann et al., 2008). This study showed that
Ab plaques form rapidly within 24 hr and subsequently recruit
activated microglia to the plaques within 1–2 days, dispelling
previous notions that microglia may actually contribute to plaque
formation. Instead, mounting evidence proves that microglia are
capable of taking up Ab. Indeed, amyloid fibrils have been
detected in microglia cultured with Ab and in AD brains (Fracko-
wiak et al., 1992; Wegiel and Wisniewski, 1990). Increased
microglial activation is also associatedwith reduced Ab accumu-
lation in human APP transgenic mice (Herber et al., 2004;
Wilcock et al., 2004; Wyss-Coray et al., 2001).
Microglia are capable of taking up soluble Ab via macropino-
cytosis (Mandrekar et al., 2009) and insoluble Ab aggregates
via phagocytosis. Following internalization, soluble Ab appears
to be readily degraded (Mandrekar et al., 2009), but dense insol-
uble aggregates may be more difficult for microglia to handle.
Indeed, mouse microglia phagocytose large amounts of Ab
in vitro, but the majority of internalized Ab is undegraded 72 hr
after uptake (Paresce et al., 1997). In fact, when cultured with
primary dog microglia, undigested Ab (obtained from human
AD patients) can be detected in phagosomes for up to 19 days
(Frackowiak et al., 1992). However, not all proteins ingested by
microglia universally experience impaired degradation. 70%–
80% of internalized nonamyloid proteins (e.g., acetylated low-
density lipoprotein or alpha2-macroglobulin) are degraded and
released by microglia within 4 hr (Paresce et al., 1997). Unde-
graded Ab is also released bymicroglia (Chung et al., 1999), sug-
gesting that detection of Ab within microglia may not prove its
clearance. As a result, the effectiveness of microglia in amyloidclearance has come into question. Recent studies suggest that
microglia are ineffective during neurodegenerative disease
because they are ill equipped for the job. In a mouse model of
AD, old PS1-APP mice have a 2- to 5-fold decrease in Ab-bind-
ing scavenger receptors and Ab-degrading enzymes, despite
increases in proinflammatory cytokines (Hickman et al., 2008).
When ADmice are treated with the anti-inflammatory drug mino-
cycline, microglial activation and IL-6 levels are reduced, but
levels of various Ab species are unchanged (Fan et al., 2007).
Despite a lack of Ab clearance, minocycline-treated mice show
a significant improvement in behavioral performance. Thus,
microglia may only play a minor role in amyloid clearance, but
may become activated by protein aggregates and contribute
to secondary degeneration via release of neurotoxic factors.
The consequences and, most importantly, the significance of
microglial interactions with Ab in AD remain unclear. This is in
part due to the plethora of different experimental settings used
in published studies, including different types and sources of
Ab assemblies (which may recruit different receptors on micro-
glia), different cell types (neonatal versus adult primary cells, or
cell lines), and cell culture versus in vivo. To develop disease-
relevant findings, putative Ab receptors need to be tested in
loss- and gain-of-function animal models and ideally in more
than one AD animal model.
Cerebral Infiltration of Immune Cells
in Neurodegeneration
In models where effective amyloid clearance is observed, it has
recently been attributed to infiltrating monocytes or perivascular
macrophages, which seem to readily degrade amyloid (Hawkes
and McLaurin, 2009; Majumdar et al., 2008). This disparity may
be explained by microglial lysosomes being less acidic than
macrophage lysosomes, resulting in reduced activity of lyso-
somal enzymes (Majumdar et al., 2007). Indeed, treating micro-
glia with macrophage colony stimulating factor (M-CSF) acidifies
microglial lysosomes to levels comparable to macrophages and
facilitates Ab degradation (Majumdar et al., 2007). Although
CNS-infiltrating monocytes appear beneficial for amyloid clear-
ance, their role in human neurodegenerative disease remains
unclear. This has been a source of controversy because initial
studies implicating blood-derived monocytes in promoting Ab
clearance used a bone marrow irradiation model to track GFP
monocytes into the diseased brain (Simard et al., 2006). This
model is not ideal because irradiation itself may damage the
BBB and activate the peripheral immune system, thus augment-
ing cellular infiltration. More recent studies using parabiosis
(a technique that allows shared vasculature between two mice)
showed that when wild-type mice are joined with GFP mice,
GFP monocytes do not enter the brain under normal conditions
or after CNS insult (Ajami et al., 2007). Only whenmice encounter
irradiation and bone marrow transplants do bone-marrow-
derived monocytes infiltrate the brain. A complementary study
also showed that bone-marrow-derived cells do not contribute
to microglial populations unless the brain is irradiated (Mildner
et al., 2007). This study provided further insight by characterizing
a specific bone-marrow-derived cell population that infiltrates
the brain after irradiation (Ly-6Chi CCR2+ cells) and identified
the importance of the chemokine receptor CCR2 in thisNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 115
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Disease
Protein
Aggregates Infiltrating Cell Type
Beneficial or
Detrimental Experimental Model Irradiation Reference
ALS mSOD1 monocytes role unknown mSOD1 yes Kang and Rivest, 2007
CD4+ T cells + mSOD1 no Beers et al., 2008; Chiu et al., 2008
human n/a Engelhardt et al., 1993
CD8+ T cells role unknown mSOD1 no Beers et al., 2008; Chiu et al., 2008
human n/a Engelhardt et al., 1993
NK cells role unknown mSOD1 no Chiu et al., 2008
Alzheimer’s
Disease
Ab, Tau monocytes + Appswe/PS1, APP23 yes Malm et al., 2005; Simard et al., 2006;
Stalder et al., 2005
Tg2576/TGFb DNR no Town et al., 2008
T cells + human no Rogers et al., 1988; Togo et al., 2002
APP/IFN-g Monsonego et al., 2006
Huntington’s
Disease
Huntingtin no reported
studies found
Mhtt, human
Parkinson’s
Disease
a-synuclein monocytes role unknown MPTP yes Kokovay and Cunningham, 2005;
Rodriguez et al., 2007
CD4+ T cells – MPTP, human no Brochard et al, 2009; Kurkowska-
Jastrzebska et al., 1999
CD8+ T cells role unknown MPTP, human no Brochard et al., 2009; Kurkowska-
Jastrzebska et al., 1999; McGeer
et al., 1988
Prion Disease Prp-amyloid monocytes role unknown scrapie yes Priller et al., 2006; Williams et al., 1995
T cells (CD4,8) – scrapie no Betmouni et al., 1996
SCID + intracerebral ME7 yes Blattler et al., 1997; Fraser et al., 1996
Aging Reelin T cells (CD4,8) role unknown aged Lewis rat, mice no Bradl et al., 2005; Knuesel et al., 2009migration. In support of this concept, recent studies in amodel of
liver injury and peripheral inflammation suggested that fluores-
cently tagged monocytes can infiltrate the brain in a chemokine
receptor CCR2-dependent manner (D’Mello et al., 2009). While
such studies are technically challenging and need to be
confirmed, they indicate that specific signaling pathways may
allow the CNS to recruit monocytes from the periphery.
Additional studies indicate the chemokine CCL2 and its
receptor CCR2 play a key role in regulating the infiltration of
peripheral monocytes into the brain. Lack of CCR2 in mice
results in reduced accumulation of microglia/monocytes in the
brain and accelerates disease progression and Ab deposition
in a mouse model of AD (El Khoury et al., 2007). Because micro-
glia from CCR2/ mice do not exhibit aberrant proliferation
(El Khoury et al., 2007), it was postulated that changes in micro-
glia accumulation are a consequence of monocyte infiltration.
Conversely, overexpressing CCL2 in the brain results in
increased microglial accumulation (Yamamoto et al., 2005).
However, overexpressing CCL2 also results in increased Ab
accumulation, which may be due to a prominent increase in
mouse APOE (Yamamoto et al., 2005), a factor known to inde-
pendently enhance Ab deposition (Bales et al., 1999). Recent
studies also suggest that infiltrating monocytes may originate
from a subpopulation of CD11cmonocytes when TGFb signaling
is impaired (Town et al., 2008). These cells appear to infiltrate
and clear Ab in a mouse model of AD (Town et al., 2008). While
CD11c-expressing cells may indeed come from the periphery,116 Neuron 64, October 15, 2009 ª2009 Elsevier Inc.recent reports show that CD11c microglia exist within the CNS
under pathological and nonpathological conditions and may
provide a pool for endogenous expansion in the absence of
TGFb signaling (Bulloch et al., 2008; Chiu et al., 2008).
In summary, flow cytometry has been used to describe several
profiles, including CD45highCD11b+, Ly-6ChighCCR2+, and
CD45+CD11b+CD11c+ (Mildner et al., 2007; Sedgwick et al.,
1991; Town et al., 2008), which might identify monocytes that
have recently infiltrated the brain. However, because microenvi-
ronmental changes in the CNS during an insult may alter expres-
sion profiles of microglia, resulting in profiles that resemble
peripheralmonocytes (Ponomarev et al., 2005), there is still doubt
about the extent of monocyte recruitment into the CNS and the
role these cells play in disease. Genetic models that prevent
monocyte trafficking (e.g., P-selectin and a4 integrin knockouts;
D’Mello et al., 2009; Kerfoot et al., 2006) might offer an opportu-
nity to better define the role of resident microglia versus infil-
trating monocytes in neurodegenerative disease models.
While this debate over monocytes infiltrating the brain con-
tinues, various other peripheral immune cells are clearly present
during neurodegenerative disease (see Table 1). Maybe most
surprisingly, T cells have been detected in nearly all neurodegen-
erative diseases studied, albeit in small numbers (see Table 1).
And while these cells are seen as the culprit in diseases such
as MS, new data in chronic neurodegeneration paint a more
complex picture. Using a series of sophisticated genetic studies,
three independent groups showed recently in ALS models that
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disease while adoptive transfer of T cells ameliorated disease
(Banerjee et al., 2008; Beers et al., 2008; Chiu et al., 2008). Mean-
while, in a mouse model of Parkinson’s disease, dopaminergic
cell death is markedly attenuated in the absence of T cells (Bro-
chard et al., 2009). Similarly, mice lacking T and B cells are resis-
tant to prion disease following intraperitoneal or intracerebral
ME7 scrapie injection (Fraser et al., 1996). In this model, immune
cells may cause degeneration, but may also be responsible for
replication and transfer of the prion particles to the CNS (Blattler
et al., 1997; Fraser et al., 1996). Interestingly, even if immune
cells do not directly access CNS parenchyma, new studies
suggest that T cells and polymorphonuclear leukocytes may
promote seizures and subsequent degeneration by binding to
the luminal side of cerebral blood vessels (Fabene et al., 2008).
Consequently, inhibiting leukocyte-vascular interactions via
blocking or deleting vascular adhesion molecules markedly
reduced seizures. While this concept is seemingly tangential to
common neurodegenerative disease, the fact that AD mice
and certain patients show underlying seizure activity lends rele-
vance to the possibility of these mechanisms contributing to
disease pathogenesis (Amatniek et al., 2006; Palop et al.,
2007). Currently, it is unclear whether Ab aberrantly excites the
neurocircuitry or recruits immune cells to CNS vasculaturewhere
interactions promote seizures, but this could be experimentally
tested using APPmice deficient in vascular adhesion molecules.
Soluble Immune Factors Allow Crosstalk between
the Periphery and CNS
If peripheral immune cells can be mobilized to the CNS during
neurodegenerative disease, the CNS and periphery must
engage in crosstalk that likely involves soluble factors. As
mentioned above, CCL2 may function as a chemoattractant for
peripheral monocytes (El Khoury et al., 2007), but many other
factors could participate in regulating interactions between
CNS and periphery. Such communication could involve proteins
classically assigned to the immune system, including acute
phase proteins, complement, cytokines, and chemokines,
although these communication factors can be the source or
target of many other tissues, including the brain. Indeed, many
classical immune regulatory factors are produced by glial cells
or neurons in the CNS and increased during injury. On the other
hand, neurodegenerative changes in the brain appear to be
associated with changes in the peripheral immune system. For
example, freshly isolated peripheral blood mononuclear cells
(PBMCs) from AD patients produce higher levels of IL-1b, IL-6,
and oncostatin M than cells from nondemented controls (Reale
et al., 2005). Using more global approaches, microarray analysis
of PBMCs and lymphocytes from AD patients show a prominent
gene dysregulation when compared to age-matched controls
(Fiala et al., 2007; Kalman et al., 2005; Maes et al., 2007). Simi-
larly, changes in patterns of soluble immunemediators and other
communication factors in the periphery have been linked to AD,
HD, and PD and were used to predict disease progression
(Bjorkqvist et al., 2008; Ray et al., 2007; Scherzer et al., 2007).
For example, elevated IL-6 levels were observed in preclinical
HD mutation carriers up to 16 years before the onset of motor
abnormalities (Bjorkqvist et al., 2008), and changes in the levelsof 18 cellular communication factors in plasma predicted AD
progression several years prior to clinical manifestation (Ray
et al., 2007). Indeed, some of these 18 proteins have been linked
mechanistically to AD or AD-like disease inmice, although others
may be unrelated or false-positive findings. Overall, whether
changes in immune function or expression of soluble mediators
in the periphery affect neurodegeneration is still unclear.
However, expanding the search for changes in cellular commu-
nication factors (which we dubbed the cellular communicome) in
neurodegenerative disease to hundreds of proteins and
increasing the number of patient samples could provide support
for systemic dysregulation of biological pathways. If successful,
proteins or biological pathways, which change as a result of neu-
rodegeneration, could become targets for treatments, and
groups of proteins might be used as diagnostic signatures and
for disease therapy monitoring.
Currently, it is unknown whether altered peripheral communi-
cation factors in neurodegenerative disease are actively pro-
duced in the periphery, derived from the CNS, or both. It is
also unclear whether these changes in peripheral immune
factors are merely a correlate of CNS degeneration or actually
impact disease progression. Emerging evidence is beginning
to suggest the latter: that altering peripheral inflammation during
neurodegenerative disease can significantly alter disease course
(Perry et al., 2007). In support of this, studies show that systemic
inflammatory challenges in mouse models of ALS, optic nerve
crush, PD, and prion disease lead to exaggerated CNS inflam-
mation and a significant increase in neurodegeneration, culmi-
nating in accelerated disease progression (Cunningham et al.,
2005; Frank-Cannon et al., 2008; Nguyen et al., 2004; Palin
et al., 2008). Similarly, in humans with AD, systemic infections
and elevated plasma levels of IL-1b are both associated with
an increased rate of cognitive dysfunction (Holmes et al.,
2003). Chronic systemic expression of IL-1b in mouse models
of PD enhances CNS inflammation and neurodegeneration
(Godoy et al., 2008). In light of these findings, it is tempting to
speculate that chronic peripheral inflammation may accelerate
neurodegenerative disease. This theory may explain the
reported epidemiological benefits of NSAIDs in AD and PD
(Chen et al., 2005; McGeer et al., 1996; Vlad et al., 2008), where
individuals may have an underlying inflammatory condition, but
the lack of a beneficial effect in clinical trials where individuals
with ancillary inflammatory conditions are excluded. If true,
determining which types of chronic inflammation (i.e., arthritis,
inflammatory bowel disease, infections, etc.) exacerbate neuro-
degenerative disease and finding effective treatments for these
disorders will be critical for reducing overall disease progression.
Aside from intercellular communication factors, antibodies
have also recently received much attention as peripheral
immune molecules with a possible role in AD and other neurode-
generative diseases. Stimulating the production of Ab antibodies
by active immunization with synthetic Ab (Schenk et al., 1999) or
administering monoclonal Ab antibodies (DeMattos et al., 2001;
Levites et al., 2006) is being actively pursued as a potential
treatment for AD and is discussed in the accompanying review
by Yong and Rivest 2009 ([this issue of Neuron]). Interestingly,
antibodies against Ab occur naturally in blood and CSF in free
form or in complex with Ab, both in AD patients and healthyNeuron 64, October 15, 2009 ª2009 Elsevier Inc. 117
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Reviewindividuals (reviewed in Szabo et al., 2008). Although titers of
these antibodies are low, naturally occurring antibodies recog-
nizing known toxic oligomeric Ab and amyloidogenic non-Ab
species are abundant in healthy humansandnonhumanprimates
and decrease with age and advancing AD (Britschgi et al., 2009).
Plasma IgGs are capable of reducing some of Ab’s neurotoxicity,
and plasma Ab antibodies may facilitate the clearance of Ab, but
more studies are necessary to understand the role of these anti-
bodies in vivo.
Summary
The past few years have generated new links between the brain
and immune system at a fervent pace and to a growing number
of neuroscientists the names of immunemolecules have become
familiar, if not interesting. Given that many of these new links
between the CNS and immune system were unexpected, neuro-
scientists and immunologists should take a humble step back
and consider the factors they study (e.g., neurotransmitters or
cytokines) as just that—factors in a complex organism that func-
tion based on their sequence and structure, not their anointed
‘‘immune’’ or ‘‘neuro’’ classification. Indeed, emerging studies
highlighting the role of ‘‘immune molecules’’ such as comple-
ment and class I major histocompatibility complex in CNS devel-
opment and plasticity (Huh et al., 2000; Stevens et al., 2007; and
see review article in this issue by Boulanger [2009]) or ‘‘CNS
factors’’ such as neurotransmitters in shaping immune function
(Pocock and Kettenmann, 2007) attest to the disregard of
proteins for classification. Moreover, while there is clearly strong
support for a role of classical inflammatory cytokines such as
TNF-a in neurodegeneration and a toxic gain of function by
microglia, there are exciting experiments involving immune acti-
vation in neurodegeneration that leave room for loss-of-function
paradigms. Apart from vaccines, however, medicine has clearly
been more successful in inhibiting the immune system rather
than activating it, and caution must be taken when attempting
to boost microglia or macrophage function. In the meantime,
we need to understand the molecular changes in immune cell
function that occur with normal healthy aging, be it in the brain
or in the peripheral immune system.
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